Please assess the completion status of the following clinical trial:

Trial Title: The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
For adults and seniors:~Inclusion Criteria:~* Healthy adults aged 18-60 years old, and healthy seniors aged \> 60 years old;~* Without vaccination history of seasonal split influenza vaccine in the recent 3 years~* No traveling plan during the study period of this trial;~* Be able to understand and sign the informed consent;~Exclusion Criteria:~* Allergic to egg products or any ingredient of the study vaccine;~* Fever, influenza or acute illness on the vaccination day;~* Acute stage of chronic illness;~* Malignant tumor;~* Immunodeficiency, includes HIV infection;~* Guillain-Barre syndrome;~* Administration of live attenuated vaccine within the previous 14 days;~* Administration of subunit or inactivated vaccine within the previous 7 days;~* Planned to participate in any other clinical trial of drug or vaccine during this study;~* Received immunesuppressive treatment within the previous month, or planned for such treatment during this study;~* Pregnant, or planning pregnancy;~* Axillary temperature \> 37.0℃;~* Any other factors that, in the judgment of the investigator, is unsuitable for this study;~For infants:~Inclusion Criteria:~* Healthy male or female aged between 6 and 35 months;~* Full-term birth, birth weight 2,500 grams or more;~* Provided birth certification or vaccination card~* Parent or legal guardian is able to understand and sign the informed consent;~Exclusion Criteria:~* Received seasonal influenza vaccine after June 30, 2012;~* Acute infection within the previous week;~* Allergy history, or allergic to any ingredient of the study vaccine, such as egg;~* History of serious adverse reaction (SAR) to vaccine;~* Autoimmune disease or immune deficiency, or administration of immunosuppressive therapy, cell toxic therapy, or inhaled corticosteroid within the previous 6 months;~* Congenital malformations, developmental disorder or serious chronic disease;~* Unstable condition of asthma and administration of corticosteroid in the most recent two years;~* Coagulation abnormalities or disorders;~* History/ family history of infantile convulsion, epilepsy, cerebropathy, or mental disease;~* Without spleen;~* Severe neurological diseases, such as Guillain-Barre syndrome;~* Administration of blood products or investigational drug within the previous month;~* Administration of live attenuated vaccine within the previous 14 days;~* Administration of subunit or inactivated vaccine within the previous 7 days;~* Received treatment for allergy within the previous 14 days;~* on-going anti-tuberculosis therapy;~* Axillary temperature \> 37.0℃ immediately before vaccination;~* any other factors that, in the judgment of the investigator, is unsuitable for this study;

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- trivalent seasonal influenza vaccine (Type: EXPERIMENTAL): Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine~* 60 infants: two-dose regimen with a 28-day interval;~* 60 adults: single-dose regimen;~* 60 seniors: single-dose regimen;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete